OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays

Differences in botulinum neurotoxin manufacturing, formulation, and potency evaluation can impact dose and biological activity, which ultimately affect duration of action. The potency of different labeled vials of incobotulinumtoxinA (Xeomin(®); 50 U, 100 U, or 200 U vials; incobotA) versus onabotul...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Toxins (Basel)
Auteurs principaux: Rupp, David, Nicholson, Greg, Canty, David, Wang, Joanne, Rhéaume, Catherine, Le, Linh, Steward, Lance E., Washburn, Mark, Jacky, Birgitte P., Broide, Ron S., Philipp-Dormston, Wolfgang G., Brin, Mitchell F., Brideau-Andersen, Amy
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7354455/
https://ncbi.nlm.nih.gov/pubmed/32545832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/toxins12060393
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires